Astria Therapeutics (ATXS) announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience. Agarwal currently serves on the Board of Directors of Arvinas and was previously a Board member of Calithera Biosciences (CALA), MyoKardia, and Vitrisa Therapeutics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Astria Therapeutics price target raised to $22 from $17 at Wedbush
- Spyre Therapeutics price target raised to $54 from $36 at Stifel
- Astria: ‘Positive’ initial proof-of-concept results from STAR-0215 for HAE trial
- Astria Therapeutics, Inc. Is Worried About This – Should You Be Worried Too?
- Astria Therapeutics reports Q4 EPS (86c), consensus (78c)
